Comparative Effects of Low-Dose Rosuvastatin, Placebo and Dietary Supplements on Lipids and Inflammatory Biomarkers (JACC)

Speakers: Drs. C. Michael Gibson, Steve Nissen and Luke Laffin
Drs. Nissen, Laffin and Gibson discuss their JACC and AHA 2022 late-breaking science results from the SPORT trial comparing to rosuvastatin, placebo and six common dietary supplements in patients at risk of ASCVD.
#AHA22

свернуть